---
title: Implant Retained Overdenture VERSUS Implant Canine Retained Overdenture.
nct_id: NCT07046104
overall_status: COMPLETED
phase: NA
sponsor: Mansoura University
study_type: INTERVENTIONAL
primary_condition: Oral Health Impact Profile Short Version 14 (OHIP 14)
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07046104.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07046104"
ct_last_update_post_date: 2025-07-01
last_seen_at: "2026-05-12T06:41:04.484Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Implant Retained Overdenture VERSUS Implant Canine Retained Overdenture.

**Official Title:** Patient Satisfaction and Oral Health Related Quality of Life for Implant Retained Overdenture VERSUS Implant Canine Retained Overdenture. Crossover Clinical Study.

**NCT ID:** [NCT07046104](https://clinicaltrials.gov/study/NCT07046104)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** Mansoura University
- **Conditions:** Oral Health Impact Profile Short Version 14 (OHIP 14)
- **Start Date:** 2023-01-12
- **Completion Date:** 2024-08-07
- **CT.gov Last Update:** 2025-07-01

## Brief Summary

ABSTRACT Background: mandibular class 1 modification 1 RPD can be retained by mesially placed implant only, or canines can be used to share in retention using telescopic attachment. So, the aim of this clinical study is to evaluate patient satisfaction and oral health impact profile (OHIP-14) for implant retained Overdenture versus implant-tooth retained Overdenture.

Methods: This clinical cross-over study included 10 partially edentulous patients with only remaining mandibular canines. Every patient received two mandibular implants at the 1st premolar region. Two mandibular implant retained overdenture will be constructed, opposing a maxillary single denture. One of the dentures was made with a design based on implant retention only but the other denture was made with dual implant-tooth retention design. The effects of each overdenture design were evaluated after 3 months. patients indicated satisfaction with their prosthesis using a visual analog scale (VAS)Regarding VAS, participants were asked to score their answer according to the amount of satisfaction on a 100 mm line (Score 0 = no satisfaction at all and score 100 = complete satisfaction). The questions cover several items related to overdentures such as retention, stability, comfort, ease of cleaning, ease of speaking, ease of chewing, limited activities due to embarrassment, quality of bolus, and appearance. , and oral health impact profile (OHIP-14) was recorded for both prostheses. The Wilcoxon signed-rank test was done to compare the statistically significant difference between the two groups. SPSS ver.23. P \<.05 was considered significant.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* This research will be done on patients who were previously received 2 mesially placed implants in the 1st premolar region with only two remaining mandibular canines with opposing maxillary single denture

Exclusion Criteria:

* uncontrolled diabetic patients
```

## Arms

- **implant retained group** (ACTIVE_COMPARATOR) — two implants in molar position and two remaining canines
- **implant tooth retained group** (ACTIVE_COMPARATOR) — implant in molar position and two remaining canines

## Interventions

- **implant retained overdenture prosthesis** (OTHER) — implant retained only prosthesis
- **implant canine retained overdenture prosthesis** (OTHER) — prosthesis retention from implant and canine

## Primary Outcomes

- **patients indicated satisfaction with their prosthesis using a visual analog scale (VAS)** _(time frame: 3 months)_

## Secondary Outcomes

- **oral health impact profile (OHIP-14) was recorded for both prostheses.** _(time frame: 3 months)_

## Locations (1)

- Basmsa, Al Mansurah, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.basmsa|al mansurah||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07046104.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07046104*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*